<p>Shikiar Asset Management Inc. 在最近向证券交易委员会的披露中表示，在第三季度减少了对 Incyte Corporation (NASDAQ:INCY - 免费报告) 的持股，降幅为 15.8%。该机构投资者在本季度出售了 18,045 股后，持有 95,950 股这家生物制药公司的股票。Incyte 在 Shikiar Asset Management Inc. 的投资组合中占约 2.0%，是其第 15 大持仓。Shikiar Asset Management Inc. 在 Incyte 的持股在最近一个季度末价值为 8,138,000 美元。</p>
<ul>
<li>Incyte 能否实现 447% 的每股收益预测和管道热度？</li>
</ul>
<p>其他机构投资者也买卖了该公司的股票。捷克国家银行在第二季度将其在 Incyte 的持股增加了 6.4%。捷克国家银行目前持有 39,271 股这家生物制药公司的股票，价值 2,674,000 美元，此前在上个季度增持了 2,378 股。denkapparat Operations GmbH 在第二季度将其在 Incyte 的持仓增加了 46.1%。denkapparat Operations GmbH 目前持有 11,292 股这家生物制药公司的股票，价值 769,000 美元，此前增持了 3,564 股。Hussman Strategic Advisors Inc. 在第二季度将其在 Incyte 的持股增加了 20.0%。Hussman Strategic Advisors Inc. 目前持有 63,000 股这家生物制药公司的股票，价值 4,290,000 美元，此前增持了 10,500 股。Fisher Asset Management LLC 在第二季度将其在 Incyte 的持股增加了 74.6%。Fisher Asset Management LLC 目前持有 29,922 股这家生物制药公司的股票，价值 2,038,000 美元，此前增持了 12,785 股。最后，Strid Group LLC 在第二季度购买了价值 999,000 美元的 Incyte 新股。机构投资者目前持有该公司 96.97% 的股票。</p>
<h2>内部人士下注</h2>
<p>在其他 Incyte 的新闻中，执行副总裁 Steven H. Stein 于 12 月 2 日星期二出售了 20,105 股该股票。股票以平均价格 102.51 美元出售，总交易额为 2,060,963.55 美元。出售完成后，该执行副总裁直接持有 63,129 股公司股票，价值约 6,471,353.79 美元。这代表其持股减少了 24.15%。该交易在向 SEC 的文件中披露，可以通过此链接访问。此外，内部人士 Thomas Tray 于 12 月 19 日星期五出售了 2,774 股公司的股票。股票以平均价格 100.00 美元出售，总交易额为 277,400.00 美元。出售完成后，该内部人士在公司中持有 22,973 股，价值 2,297,300 美元。这代表其持股减少了 10.77%。该销售的披露在 SEC 文件中可用。内部人士在过去三个月内共出售了价值 8,708,893 美元的 88,318 股公司股票。当前 17.80% 的股票由内部人士持有。</p>
<h2>Incyte 关键新闻</h2>
<ul>
<li>2024 年盈利增长的 5 大医疗保健股票</li>
</ul>
<p>以下是本周影响 Incyte 的关键新闻：</p>
<ul>
<li>积极情绪：日本批准扩大商业足迹——日本卫生当局批准了 Zynyz® (retifanlimab) 用于一线晚期肛门癌，并批准了 Minjuvi® (tafasitamab) 与利妥昔单抗和来那度胺联合用于复发/难治性滤泡淋巴瘤，为一个重要市场开辟了增量收入机会。阅读更多。阅读更多。</li>
<li>积极情绪：分析师动能和目标价格上调——几家公司最近提高了 INCY 的目标或进行了升级（例如 Guggenheim 和 Barclays），这支持了中期收入/盈利的积极叙述。阅读更多。</li>
<li>中性情绪：价格走势显示投资者兴趣但仍存谨慎——Zacks 的一篇文章指出，前一交易日的交易量超过平均水平，股价上涨约 5.5%，但警告称最近的盈利预测修订可能限制短期上涨，暗示在没有进一步数据的情况下，动能可能不持久。阅读更多。</li>
<li>消极情绪：内部人士出售可能增加卖压——董事/高管 Thomas Tray 披露在 12 月 18 日至 19 日期间共出售 3,374 股（平均价格约为 98–100 美元），并报告了其他内部人士交易；集中内部人士出售可能会发出短期压力信号或促使投资者保持谨慎。</li>
</ul>
<h2>Incyte 股票下跌 1.9%</h2>
<p>NASDAQ INCY 的股票在星期二开盘价为 100.71 美元。该公司的流动比率为 3.20，速动比率为 3.13，债务与股本比率为 0.01。该股票的市值为 197.7 亿美元，市盈率为 16.87，市盈增长比率为 0.70，贝塔值为 0.81。该股票的 50 日简单移动平均线为 98.53 美元，200 日简单移动平均线为 85.09 美元。Incyte Corporation 的 12 个月低点为 53.56 美元，12 个月高点为 109.28 美元。</p>
<ul>
<li>Argenx 的 28% 激增及有前景的产品提升投资者信心</li>
</ul>
<p>Incyte (NASDAQ:INCY - 获取免费报告) 最近于 10 月 28 日星期二发布了季度财报。这家生物制药公司报告本季度每股收益为 2.26 美元，超出市场共识预期的 1.65 美元，超出幅度为 0.61 美元。Incyte 的股本回报率为 26.56%，净利润率为 24.69%。该公司本季度的收入为 13.7 亿美元，而分析师预期为 12.6 亿美元。在去年同期，该公司每股收益为 1.07 美元。该公司的季度收入较去年同期增长了 20.0%。整体而言，分析师预计 Incyte Corporation 本财年将发布 4.86 美元的每股收益。</p>
<h2>分析师设定新目标价格</h2>
<p>几位研究分析师最近对 INCY 股票发表了评论。Stifel Nicolaus 将 Incyte 的股票目标价从 110.00 美元上调至 115.00 美元，并在 9 月 22 日的研究报告中给予该股票 “买入” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Incyte 股票的 “持有（c+）” 评级。摩根士丹利将 Incyte 的目标价从 86.00 美元上调至 92.00 美元，并在 12 月 8 日的报告中给予该公司 “等权重” 评级。Piper Sandler 将 Incyte 的目标价从 82.00 美元上调至 102.00 美元，并在 11 月 4 日的报告中给予该股票 “超配” 评级。最后，巴克莱将 Incyte 的目标价从 101.00 美元上调至 115.00 美元，并在 11 月 24 日的研究报告中给予该股票 “超配” 评级。八位投资分析师对该股票给予了 “买入” 评级，十一位给予了 “持有” 评级，一位则给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价为 99.07 美元。</p>
<p><strong>阅读我们关于 Incyte 的最新股票分析</strong></p>
<h2>关于 Incyte</h2>
<p>（免费报告）</p>
<p>Incyte Corporation 是一家总部位于特拉华州威尔明顿的生物制药公司，专注于肿瘤学和炎症领域新疗法的发现、开发和商业化。自 2002 年成立以来，Incyte 已从一家小型研究机构发展为一家全球企业，推进一系列内部开发和合作的资产。公司的研发工作集中在小分子药物和生物制剂上，这些药物和生物制剂能够调节与癌症、自身免疫疾病和罕见疾病相关的关键信号通路。</p>
<p>公司的旗舰产品是 Jakafi®（ruxolitinib），这是一种被批准用于治疗骨髓纤维化和真性红细胞增多症的 Janus 激酶（JAK）抑制剂。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>最后的黄金牛市</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Incyte 吗？</h2>
<p>在你考虑 Incyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Incyte 并不在名单上。</p>
<p>虽然 Incyte 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

因塞特医疗

<p>Shikiar Asset Management Inc. 在第三季度减少了对因塞特医疗的持股比例，下降了 15.8%，出售了 18,045 股。内部交易包括执行副总裁 Steven H. Stein 出售了 20,105 股，内部人士 Thomas Tray 出售了 2,774 股。因塞特医疗的股票开盘价为 100.71 美元，市值为 197.7 亿美元。近期分析师的升级和日本对关键药物的批准可能会影响未来的收益</p>

<p>Shikiar Asset Management Inc. decreased its holdings in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 15.8% during the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 95,950 shares of the biopharmaceutical company's stock after selling 18,045 shares during the quarter. Incyte comprises about 2.0% of Shikiar Asset Management Inc.'s investment portfolio, making the stock its 15th largest position. Shikiar Asset Management Inc.'s holdings in Incyte were worth $8,138,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Shikiar Asset Management Inc. 在最近向证券交易委员会的披露中表示，在第三季度减少了对 Incyte Corporation (NASDAQ:INCY - 免费报告) 的持股，降幅为 15.8%。该机构投资者在本季度出售了 18,045 股后，持有 95,950 股这家生物制药公司的股票。Incyte 在 Shikiar Asset Management Inc. 的投资组合中占约 2.0%，是其第 15 大持仓。Shikiar Asset Management Inc. 在 Incyte 的持股在最近一个季度末价值为 8,138,000 美元。</p>
</div><ul>
<li>Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>Incyte 能否实现 447% 的每股收益预测和管道热度？</li>
</ul>
</div><p>Other institutional investors have also bought and sold shares of the company. Czech National Bank lifted its stake in shares of Incyte by 6.4% during the 2nd quarter. Czech National Bank now owns 39,271 shares of the biopharmaceutical company's stock worth $2,674,000 after acquiring an additional 2,378 shares during the last quarter. denkapparat Operations GmbH grew its position in Incyte by 46.1% in the 2nd quarter. denkapparat Operations GmbH now owns 11,292 shares of the biopharmaceutical company's stock valued at $769,000 after acquiring an additional 3,564 shares during the last quarter. Hussman Strategic Advisors Inc. increased its stake in Incyte by 20.0% in the second quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the biopharmaceutical company's stock worth $4,290,000 after purchasing an additional 10,500 shares during the period. Fisher Asset Management LLC increased its stake in Incyte by 74.6% in the second quarter. Fisher Asset Management LLC now owns 29,922 shares of the biopharmaceutical company's stock worth $2,038,000 after purchasing an additional 12,785 shares during the period. Finally, Strid Group LLC bought a new stake in shares of Incyte during the second quarter worth $999,000. Institutional investors own 96.97% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者也买卖了该公司的股票。捷克国家银行在第二季度将其在 Incyte 的持股增加了 6.4%。捷克国家银行目前持有 39,271 股这家生物制药公司的股票，价值 2,674,000 美元，此前在上个季度增持了 2,378 股。denkapparat Operations GmbH 在第二季度将其在 Incyte 的持仓增加了 46.1%。denkapparat Operations GmbH 目前持有 11,292 股这家生物制药公司的股票，价值 769,000 美元，此前增持了 3,564 股。Hussman Strategic Advisors Inc. 在第二季度将其在 Incyte 的持股增加了 20.0%。Hussman Strategic Advisors Inc. 目前持有 63,000 股这家生物制药公司的股票，价值 4,290,000 美元，此前增持了 10,500 股。Fisher Asset Management LLC 在第二季度将其在 Incyte 的持股增加了 74.6%。Fisher Asset Management LLC 目前持有 29,922 股这家生物制药公司的股票，价值 2,038,000 美元，此前增持了 12,785 股。最后，Strid Group LLC 在第二季度购买了价值 999,000 美元的 Incyte 新股。机构投资者目前持有该公司 96.97% 的股票。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Incyte news, EVP Steven H. Stein sold 20,105 shares of the stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the completion of the sale, the executive vice president directly owned 63,129 shares of the company's stock, valued at approximately $6,471,353.79. This represents a 24.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Tray sold 2,774 shares of the firm's stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00. Following the completion of the sale, the insider owned 22,973 shares in the company, valued at $2,297,300. This represents a 10.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 88,318 shares of company stock valued at $8,708,893 in the last three months. 17.80% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 Incyte 的新闻中，执行副总裁 Steven H. Stein 于 12 月 2 日星期二出售了 20,105 股该股票。股票以平均价格 102.51 美元出售，总交易额为 2,060,963.55 美元。出售完成后，该执行副总裁直接持有 63,129 股公司股票，价值约 6,471,353.79 美元。这代表其持股减少了 24.15%。该交易在向 SEC 的文件中披露，可以通过此链接访问。此外，内部人士 Thomas Tray 于 12 月 19 日星期五出售了 2,774 股公司的股票。股票以平均价格 100.00 美元出售，总交易额为 277,400.00 美元。出售完成后，该内部人士在公司中持有 22,973 股，价值 2,297,300 美元。这代表其持股减少了 10.77%。该销售的披露在 SEC 文件中可用。内部人士在过去三个月内共出售了价值 8,708,893 美元的 88,318 股公司股票。当前 17.80% 的股票由内部人士持有。</p>
</div><h2>Key Incyte News</h2>
<div class="lb-trans"><h2>Incyte 关键新闻</h2>
</div><ul>
<li>5 top healthcare stocks for earnings growth in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年盈利增长的 5 大医疗保健股票</li>
</ul>
</div><p>Here are the key news stories impacting Incyte this week:</p>
<div class="lb-trans"><p>以下是本周影响 Incyte 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Japan approvals broaden commercial footprint — Japan's health authorities approved Zynyz® (retifanlimab) for first‑line advanced anal cancer and approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, opening incremental revenue opportunities in a major market. Read More. Read More.</li>
<li>Positive Sentiment: Analyst momentum and price‑target lifts — Several firms have recently raised targets or upgraded INCY (examples cited include Guggenheim and Barclays), which supports a constructive medium‑term revenue/earnings narrative. Read More.</li>
<li>Neutral Sentiment: Price action shows investor interest but cautions remain — A Zacks write‑up noted a ~5.5% prior session surge on above‑average volume but warned that recent earnings‑estimate revisions may limit near‑term upside, implying momentum may not be durable without further data. Read More.</li>
<li>Negative Sentiment: Insider selling could add selling pressure — Director/officer Thomas Tray disclosed sales totalling 3,374 shares across Dec. 18–19 (avg. ~$98–$100) and other insider transactions were reported; concentrated insider sales can signal near‑term pressure or prompt investor caution. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：日本批准扩大商业足迹——日本卫生当局批准了 Zynyz® (retifanlimab) 用于一线晚期肛门癌，并批准了 Minjuvi® (tafasitamab) 与利妥昔单抗和来那度胺联合用于复发/难治性滤泡淋巴瘤，为一个重要市场开辟了增量收入机会。阅读更多。阅读更多。</li>
<li>积极情绪：分析师动能和目标价格上调——几家公司最近提高了 INCY 的目标或进行了升级（例如 Guggenheim 和 Barclays），这支持了中期收入/盈利的积极叙述。阅读更多。</li>
<li>中性情绪：价格走势显示投资者兴趣但仍存谨慎——Zacks 的一篇文章指出，前一交易日的交易量超过平均水平，股价上涨约 5.5%，但警告称最近的盈利预测修订可能限制短期上涨，暗示在没有进一步数据的情况下，动能可能不持久。阅读更多。</li>
<li>消极情绪：内部人士出售可能增加卖压——董事/高管 Thomas Tray 披露在 12 月 18 日至 19 日期间共出售 3,374 股（平均价格约为 98–100 美元），并报告了其他内部人士交易；集中内部人士出售可能会发出短期压力信号或促使投资者保持谨慎。</li>
</ul>
</div><h2>Incyte Stock Down 1.9%</h2>
<div class="lb-trans"><h2>Incyte 股票下跌 1.9%</h2>
</div><p>Shares of NASDAQ INCY opened at $100.71 on Tuesday. The company has a current ratio of 3.20, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $19.77 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 0.70 and a beta of 0.81. The stock's fifty day simple moving average is $98.53 and its two-hundred day simple moving average is $85.09. Incyte Corporation has a 12-month low of $53.56 and a 12-month high of $109.28.</p>
<div class="lb-trans"><p>NASDAQ INCY 的股票在星期二开盘价为 100.71 美元。该公司的流动比率为 3.20，速动比率为 3.13，债务与股本比率为 0.01。该股票的市值为 197.7 亿美元，市盈率为 16.87，市盈增长比率为 0.70，贝塔值为 0.81。该股票的 50 日简单移动平均线为 98.53 美元，200 日简单移动平均线为 85.09 美元。Incyte Corporation 的 12 个月低点为 53.56 美元，12 个月高点为 109.28 美元。</p>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及有前景的产品提升投资者信心</li>
</ul>
</div><p>Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 EPS for the quarter, topping the consensus estimate of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the company posted $1.07 EPS. The business's revenue for the quarter was up 20.0% compared to the same quarter last year. As a group, analysts expect that Incyte Corporation will post 4.86 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Incyte (NASDAQ:INCY - 获取免费报告) 最近于 10 月 28 日星期二发布了季度财报。这家生物制药公司报告本季度每股收益为 2.26 美元，超出市场共识预期的 1.65 美元，超出幅度为 0.61 美元。Incyte 的股本回报率为 26.56%，净利润率为 24.69%。该公司本季度的收入为 13.7 亿美元，而分析师预期为 12.6 亿美元。在去年同期，该公司每股收益为 1.07 美元。该公司的季度收入较去年同期增长了 20.0%。整体而言，分析师预计 Incyte Corporation 本财年将发布 4.86 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价格</h2>
</div><p>Several research analysts recently commented on INCY shares. Stifel Nicolaus raised their price target on shares of Incyte from $110.00 to $115.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, September 22nd. Weiss Ratings reaffirmed a &#34;hold (c+)&#34; rating on shares of Incyte in a research note on Wednesday, October 8th. Morgan Stanley boosted their price target on Incyte from $86.00 to $92.00 and gave the company an &#34;equal weight&#34; rating in a report on Monday, December 8th. Piper Sandler upped their target price on Incyte from $82.00 to $102.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, November 4th. Finally, Barclays increased their price target on Incyte from $101.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 24th. Eight investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus target price of $99.07.</p>
<div class="lb-trans"><p>几位研究分析师最近对 INCY 股票发表了评论。Stifel Nicolaus 将 Incyte 的股票目标价从 110.00 美元上调至 115.00 美元，并在 9 月 22 日的研究报告中给予该股票 “买入” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Incyte 股票的 “持有（c+）” 评级。摩根士丹利将 Incyte 的目标价从 86.00 美元上调至 92.00 美元，并在 12 月 8 日的报告中给予该公司 “等权重” 评级。Piper Sandler 将 Incyte 的目标价从 82.00 美元上调至 102.00 美元，并在 11 月 4 日的报告中给予该股票 “超配” 评级。最后，巴克莱将 Incyte 的目标价从 101.00 美元上调至 115.00 美元，并在 11 月 24 日的研究报告中给予该股票 “超配” 评级。八位投资分析师对该股票给予了 “买入” 评级，十一位给予了 “持有” 评级，一位则给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价为 99.07 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Incyte</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Incyte 的最新股票分析</strong></p>
</div><h2>About Incyte</h2>
<div class="lb-trans"><h2>关于 Incyte</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.</p>
<div class="lb-trans"><p>Incyte Corporation 是一家总部位于特拉华州威尔明顿的生物制药公司，专注于肿瘤学和炎症领域新疗法的发现、开发和商业化。自 2002 年成立以来，Incyte 已从一家小型研究机构发展为一家全球企业，推进一系列内部开发和合作的资产。公司的研发工作集中在小分子药物和生物制剂上，这些药物和生物制剂能够调节与癌症、自身免疫疾病和罕见疾病相关的关键信号通路。</p>
</div><p>The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.</p>
<div class="lb-trans"><p>公司的旗舰产品是 Jakafi®（ruxolitinib），这是一种被批准用于治疗骨髓纤维化和真性红细胞增多症的 Janus 激酶（JAK）抑制剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Incyte</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>最后的黄金牛市</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=INCY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Incyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Incyte 吗？</h2>
</div><p>Before you consider Incyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Incyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Incyte 并不在名单上。</p>
</div><p>While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Incyte 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Shikiar 资产管理公司减少了其在因塞特医疗公司$INCY 的股票持仓